Get the Stockscreener App
1.55
1.59%
-0.025
After Hours:
1.55
Pliant Therapeutics Inc stock is traded at $1.55, with a volume of 1.08M.
It is down -1.59% in the last 24 hours and up +11.51% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.575
Open:
$1.6
24h Volume:
1.08M
Relative Volume:
0.88
Market Cap:
$95.15M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.5016
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
-6.63%
1M Performance:
+11.51%
6M Performance:
-49.01%
1Y Performance:
-87.53%
1-Day Range:
$1.54
$1.65
1-Week Range:
$1.45
$1.72
52-Week Range:
$1.1001
$16.10
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.55 | 96.69M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Will Pliant Therapeutics Inc. Sustain Its Chart BreakoutPortfolio Return Report & Weekly High Conviction Ideas - beatles.ru
Short Interest Drops in Pliant Therapeutics Inc. After Rally2025 Support & Resistance & Growth Focused Stock Reports - newsyoung.net
Is Pliant Therapeutics Inc. currently under institutional pressureJuly 2025 Sector Moves & Verified Momentum Stock Ideas - metrotimes.co.kr
Pliant Therapeutics Reports Q2 2025 Financial Results - TipRanks
Is Pliant Therapeutics Inc. a defensive stockMarket Volume Summary & Free High Accuracy Swing Entry Alerts - thegnnews.com
Citi Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $1.7 - 富途牛牛
Citi Raises Pliant Therapeutics Price Target to $1.70 Amid Unclear Path Forward - AInvest
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
Citi Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX) - The Globe and Mail
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $1.7 to $4 - 富途牛牛
Pliant Therapeutics Pivots To Oncology After Ending IPF Program - Finimize
Pliant Therapeutics shares fall 1.25% intraday after workforce realignment and BEACON-IPF closure. - AInvest
RBC Capital Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $3 - 富途牛牛
Pliant Therapeutics stock price target slashed by Piper Sandler - Investing.com Canada
Needham Maintains Pliant Therapeutics(PLRX.US) With Hold Rating - 富途牛牛
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - 富途牛牛
Pliant Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pliant Therapeutics reports Q2 EPS (71c), consensus (68c) - TipRanks
Pliant Therapeutics Q2 net loss narrows - MarketScreener
Pliant Therapeutics reports Q2 FY25 financial results, Phase 1 oncology trial on track. - AInvest
Pliant Therapeutics shares rise 2.65% intraday after IDEAYA Biosciences reports positive Phase 2/3 trial data. - AInvest
Should I hold or sell Pliant Therapeutics Inc. stock in 2025Tremendous financial leverage - Jammu Links News
Pliant Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - Jammu Links News
How many analysts rate Pliant Therapeutics Inc. as a “Buy”Identify undervalued stocks ready to soar - Jammu Links News
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $3 to $17 - 富途牛牛
How volatile is Pliant Therapeutics Inc. stock compared to the marketDiscover hidden gems in the stock market - Jammu Links News
How does Pliant Therapeutics Inc. compare to its industry peersInvest confidently with market-leading analysis - Jammu Links News
Is Pliant Therapeutics Inc. a good long term investmentInvest confidently with expert support - Jammu Links News
Does Pliant Therapeutics Inc. stock perform well during market downturnsAchieve rapid portfolio growth with expert guidance - Jammu Links News
What is the risk reward ratio of investing in Pliant Therapeutics Inc. stockGame-changing returns - Jammu Links News
What makes Pliant Therapeutics Inc. stock price move sharplyFree Stock Market Return Analysis - Jammu Links News
What are Pliant Therapeutics Inc. company’s key revenue driversDiscover undervalued opportunities early - Jammu Links News
What is Pliant Therapeutics Inc. company’s growth strategyBuild wealth steadily with smart stock selection - Jammu Links News
Pliant Therapeutics Inc. Trading Near Value Zone — Recovery AheadTop Performing Stock Insights Released Daily - metal.it
What are analysts’ price targets for Pliant Therapeutics Inc. in the next 12 monthsAdvanced Screener Planner For 2025 - Jammu Links News
Competitive Positioning of Pliant Therapeutics Inc.: Is It Leading or LaggingWeekly Return Pick Forecast Reports Show Trend - metal.it
Published on: 2025-07-30 01:15:54 - metal.it
Bollinger Bands Expand on Pliant Therapeutics Inc. — Volatility AheadWatchlist for Smart Swing Trading Updated - beatles.ru
Will Pliant Therapeutics Inc. stock split in the near futureInvestment Playbook for Growing Markets Shared - metal.it
Pliant Therapeutics Inc. Sees Spike in Bullish Option FlowDaily Momentum Screener With Alerts Launched - metal.it
What catalysts could drive Pliant Therapeutics Inc. stock higher in 2025Unprecedented profit potential - Jammu Links News
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pliant Therapeutics Inc Stock (PLRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):